Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
Brivaracetam (1) ·
Butorphanol (1) ·
Cannabidiol (1) ·
Cenobamate (1) ·
Clobazam (1) ·
Codeine (2) ·
Dextropropoxyphene (1) ·
Dihydrocodeine (1) ·
Eslicarbazepine (1) ·
Ethosuximide (1) ·
Ethylmorphine (1) ·
Felbamate (1) ·
Fenfluramine (1) ·
Fentanyl (1) ·
Fosphenytoin (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Lacosamide (1) ·
Levorphanol (1) ·
Meperidine (1) ·
Modafinil (1) ·
Nalbuphine (1) ·
Oxymorphone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Perampanel (1) ·
Phenobarbital (1) ·
Phenytoin (1) ·
Rufinamide (1) ·
Stiripentol (1) ·
Tapentadol (1) ·
Tiagabine (1) ·
Valproic acid (1) ·
Vigabatrin (1) ·
Zonisamide (1)
None (5) ·
(multiple, generic dominant) (1) ·
Aptiom (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Darvon (1) ·
Demerol (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
Dilaudid (1) ·
Duragesic (1) ·
Epidiolex (1) ·
Felbatol (1) ·
Fintepla (1) ·
Fycompa (1) ·
Gabitril (1) ·
Luminal (1) ·
Nubain (1) ·
Nucynta (1) ·
Onfi (1) ·
Opana (1) ·
Provigil (Teva/Cephalon); Alertec (Canada); Modavigil (Australia) (1) ·
Sabril (1) ·
Stadol (1) ·
Talwin (1) ·
Vicodin (1) ·
Vimpat (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zonegran (1)
None (1) ·
AMPA receptor antagonist (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1)
None (34) ·
30–60 min (PO) (1) ·
Peak plasma concentration in 2-4 hours after oral administration. Clinically perceptible wakefulness-promoting effects typically begin within 1-2 hours of dosing.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
None (34) ·
4–6 hours (1) ·
Effective duration approximately 12-15 hours at the 200 mg dose, consistent with the elimination half-life. A single morning dose generally sustains wakefulness throughout the day without substantially disrupting nighttime sleep onset when taken early.'"`UNIQ--ref-0000006D-QINU`"' (1)
None (34) ·
Oral bioavailability is not precisely established in the label but absorption is rapid and essentially complete. Food delays peak plasma concentration by approximately one hour but does not reduce the extent of absorption.'"`UNIQ--ref-0000006F-QINU`"' (1) ·
~50% (variable, CYP2D6-dependent for analgesic effect). (1)
Showing below up to 36 results in range #1 to #36.


